为2020年及以后设计ARDS试验:聚焦富集策略
该文为评论性文章,聚焦于ARDS临床试验设计中的患者选择优化问题。文章指出,除少数支持治疗试验外,多数ARDS干预性临床试验未能产生新疗法。改善试验设计需考虑治疗类型、试验阶段(2期或3期)、患者选择、主要和次要终点及试验实施策略(如平台试验或适应性试验)。其中优化患者选择是核心,因ARDS是异质性临床综合征而非均质疾病。文章重点讨论预后富集和预测富集的新信息与新方法,以优化患者选择并提高ARDS临床试验阳性率。
要点
- ARDS是异质性临床综合征而非均质疾病,优化患者选择是提高试验成功可能性的核心。
- 改善ARDS临床试验设计需综合考虑治疗类型、试验阶段(2期或3期)、患者选择、主要和次要终点及试验实施策略。
- 对病理生理机制理解的深入和结局预测工具的改进,有助于实现预后富集和预测富集。
- 可考虑平台试验或适应性试验等新型试验设计。
- 本文为评论性文章,聚焦预后富集和预测富集的新信息与新方法。
适用人群与场景
- 原文未提及
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 本文为评论性文章,非研究论文,未报告研究类型、样本量、干预与对照或主要终点结果。
- 文中指出:除少数支持治疗试验外,多数ARDS干预性临床试验未能产生新疗法。
- 文中指出:ARDS是异质性临床综合征而非均质疾病,优化患者选择是提高试验成功可能性的核心。
- 文中提及:对病理生理机制理解的深入和结局预测工具的改进,应有助于预后富集和预测富集。
- 文中提及:可考虑平台试验或适应性试验等新型试验设计。
证据类型、等级与局限
- 证据类型:评论性文章(非系统评价、非RCT)。
- 局限:原文未提及具体证据等级;作为评论性文章,未提供原始研究数据或系统评价方法。
对床旁实践的改变
- 原文未提及具体可改变急诊/ICU床旁实践的做法。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
With the exception of a few successes in trials of supportive care, the majority of interventional clinical trials for acute respiratory distress syndrome (ARDS) have not led to new therapies. To improve the likelihood of benefit from clinical trial interventions in ARDS, clinical trial design must be improved. To optimize trial design, many factors need to be considered including the type of therapy to be tested, the type of trial (phase 2 or 3), how patients will be selected, primary and secondary end-points, and strategy for conduct of the trial, including potential newer trial designs such as platform or adaptive trials. Of these, optimization of patient selection is central to the likelihood of success and is particularly relevant in ARDS, which is a heterogeneous clinical syndrome, not a homogeneous disease. Recent advances including improved understanding of pathophysiologic mechanisms and better tools for outcome prediction in ARDS should facilitate both predictive and prognostic enrichment. This commentary focuses on new information and novel methods for prognostic and predictive enrichment that may be useful to optimize patient selection and increase the likelihood of positive clinical trials in ARDS.
参考来源
- Ware LB, Matthay MA, Mebazaa A, et al. Designing an ARDS trial for 2020 and beyond: focus on enrichment strategies. Intensive Care Med. 2020. PMID: 33136196. doi:10.1007/s00134-020-06232-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。